Format

Send to

Choose Destination
Curr Opin Pharmacol. 2013 Aug;13(4):618-24. doi: 10.1016/j.coph.2013.05.011. Epub 2013 Jun 7.

Obesity, immunomodulation and chronic kidney disease.

Author information

1
Center for Renal Translational Medicine, Division of Nephrology-Hypertension, Department of Medicine, Institute for Metabolomic Medicine, University of California San Diego, La Jolla, CA, United States.

Abstract

Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.

PMID:
23751262
PMCID:
PMC4442271
DOI:
10.1016/j.coph.2013.05.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center